| Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness G Manokaran, E Finol, C Wang, J Gunaratne, J Bahl, EZ Ong, HC Tan, ... Science 350 (6257), 217-221, 2015 | 414 | 2015 |
| A dynamic immune response shapes COVID-19 progression EZ Ong, YFZ Chan, WY Leong, NMY Lee, S Kalimuddin, SMH Mohideen, ... Cell host & microbe 27 (6), 879-882. e2, 2020 | 305 | 2020 |
| Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset S Kalimuddin, CYL Tham, M Qui, R de Alwis, JXY Sim, JME Lim, HC Tan, ... Med 2 (6), 682-688. e4, 2021 | 193 | 2021 |
| Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue KR Chan, EZ Ong, HC Tan, SLX Zhang, Q Zhang, KF Tang, ... Proceedings of the National Academy of Sciences 111 (7), 2722-2727, 2014 | 122 | 2014 |
| Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases KR Chan, EZ Ong, DZL Mok, EE Ooi Expert review of anti-infective therapy 13 (11), 1351-1360, 2015 | 54 | 2015 |
| Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated yellow fever infection KR Chan, ES Gan, CYY Chan, C Liang, JZH Low, SLX Zhang, EZ Ong, ... Nature Medicine 25 (8), 1218-1224, 2019 | 39 | 2019 |
| A systematic approach to the development of a safe live attenuated Zika vaccine SS Kwek, S Watanabe, KR Chan, EZ Ong, HC Tan, WC Ng, MTX Nguyen, ... Nature communications 9 (1), 1031, 2018 | 39 | 2018 |
| Rational engineering and characterization of an mAb that neutralizes Zika virus by targeting a mutationally constrained quaternary epitope K Tharakaraman, S Watanabe, KR Chan, J Huan, V Subramanian, ... Cell host & microbe 23 (5), 618-627. e6, 2018 | 31 | 2018 |
| Dengue virus compartmentalization during antibody-enhanced infection EZ Ong, SL Zhang, HC Tan, ES Gan, KR Chan, EE Ooi Scientific Reports 7 (1), 40923, 2017 | 31 | 2017 |
| Therapeutic antibodies as a treatment option for dengue fever KR Chan, EZ Ong, EE Ooi Expert review of anti-infective therapy 11 (11), 1147-1157, 2013 | 31 | 2013 |
| Adverse effects following anti–COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T … A Syenina, ES Gan, JZN Toh, R de Alwis, LZ Lin, CYL Tham, JX Yee, ... PLoS Biology 20 (5), e3001643, 2022 | 28 | 2022 |
| Antibody-Dependent dengue virus entry modulates cell intrinsic responses for enhanced infection CYY Chan, JZH Low, ES Gan, EZ Ong, SLX Zhang, HC Tan, X Chai, ... Msphere 4 (5), 10.1128/msphere. 00528-19, 2019 | 24 | 2019 |
| Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates EZ Ong, Y Budigi, HC Tan, LN Robinson, KJ Rowley, A Winnett, S Hobbie, ... Antiviral research 144, 44-47, 2017 | 23 | 2017 |
| Hypoxia enhances antibody‐dependent dengue virus infection ES Gan, WF Cheong, KR Chan, EZ Ong, X Chai, HC Tan, S Ghosh, ... The EMBO Journal 36 (10), 1348-1363, 2017 | 23 | 2017 |
| Temporal dynamics of the host molecular responses underlying severe COVID-19 progression and disease resolution EZ Ong, S Kalimuddin, WC Chia, SH Ooi, CW Koh, HC Tan, SL Zhang, ... EBioMedicine 65, 2021 | 22 | 2021 |
| Viral manipulation of host inhibitory receptor signaling for immune evasion EZ Ong, KR Chan, EE Ooi PLoS pathogens 12 (9), e1005776, 2016 | 22 | 2016 |
| Phase 1 trial of a therapeutic anti–yellow fever virus human antibody JG Low, JHJ Ng, EZ Ong, S Kalimuddin, L Wijaya, YFZ Chan, DHL Ng, ... New England Journal of Medicine 383 (5), 452-459, 2020 | 21 | 2020 |
| Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein Y Budigi, EZ Ong, LN Robinson, LC Ong, KJ Rowley, A Winnett, HC Tan, ... PLoS neglected tropical diseases 12 (2), e0006209, 2018 | 21 | 2018 |
| A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine JG Low, R De Alwis, S Chen, S Kalimuddin, YS Leong, TKL Mah, N Yuen, ... npj Vaccines 7 (1), 161, 2022 | 20 | 2022 |
| Vaccination and therapeutics: responding to the changing epidemiology of yellow fever AM Bifani, EZ Ong, R de Alwis Current treatment options in infectious diseases 12, 349-360, 2020 | 19 | 2020 |
Chan Kuan RongDuke-NUSVerified email at duke-nus.edu.sg
Chan Kuan RongDuke-NUSVerified email at duke-nus.edu.sg